Nisa Investment Advisors LLC Buys 14,930 Shares of Celcuity, Inc. $CELC

Nisa Investment Advisors LLC grew its stake in Celcuity, Inc. (NASDAQ:CELC) by 2,142.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,627 shares of the company’s stock after buying an additional 14,930 shares during the period. Nisa Investment Advisors LLC’s holdings in Celcuity were worth $772,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in CELC. Avanza Fonder AB bought a new stake in shares of Celcuity during the 3rd quarter worth $79,000. Harbor Capital Advisors Inc. purchased a new stake in Celcuity during the third quarter valued at about $399,000. Red Door Wealth Management LLC purchased a new stake in Celcuity during the third quarter valued at about $389,000. Tower Research Capital LLC TRC lifted its stake in Celcuity by 211.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock worth $74,000 after purchasing an additional 3,766 shares during the last quarter. Finally, Captrust Financial Advisors boosted its holdings in shares of Celcuity by 2.3% in the 2nd quarter. Captrust Financial Advisors now owns 570,441 shares of the company’s stock worth $7,615,000 after purchasing an additional 12,838 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Insiders Place Their Bets

In other Celcuity news, Director Richard E. Buller sold 3,000 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $105.69, for a total value of $317,070.00. Following the sale, the director owned 6,760 shares of the company’s stock, valued at $714,464.40. This trade represents a 30.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 15.77% of the stock is owned by insiders.

Analysts Set New Price Targets

CELC has been the topic of a number of research reports. Guggenheim assumed coverage on Celcuity in a report on Monday, September 22nd. They set a “buy” rating on the stock. Wolfe Research assumed coverage on shares of Celcuity in a research report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price target on the stock. Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. HC Wainwright reaffirmed a “neutral” rating and issued a $94.00 price objective (up previously from $77.00) on shares of Celcuity in a research note on Monday, November 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $105.25.

Celcuity Stock Performance

Shares of CELC stock opened at $105.28 on Friday. The company has a market capitalization of $4.87 billion, a P/E ratio of -28.69 and a beta of 0.25. Celcuity, Inc. has a fifty-two week low of $7.57 and a fifty-two week high of $116.44. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The stock has a 50 day moving average price of $99.22 and a two-hundred day moving average price of $64.33.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, November 12th. The company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.13. Analysts expect that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.